{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.0","upperLimit":"40.1","value":"36.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Certolizumab pegol plasma concentration was measured at Week 2, in µg/mL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the SS.","id":"OG000","title":"CZP 200 mg Q2W (SS)"},{"description":"Subset of subjects from the Placebo group, who discontinued the CZP double-blind treatment and entered the open-label CZP treatment. The subjects were included in the SS for safety analysis.","id":"OG001","title":"Placebo->OL CZP (SS)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The SS consisted of all subjects who received at least 1 dose of study treatment. Note: No samples taken at Week 2 for the Placebo-\\>OL CZP.","reportingStatus":"POSTED","timeFrame":"Week 2","title":"Certolizumab Pegol Plasma Concentration at Week 2","type":"PRIMARY","unitOfMeasure":"µg/mL"}